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Objective: To investigate whether biochemical insoluble tau with 4 (4R) and/or 3 (3R) microtubule-binding repeats accumulate
in white as well as gray matter in progressive supranuclear palsy (PSP), a neurodegenerative tauopathy.
Methods: To assess tau pathology in PSP white matter, we combined Western blot (WB) and immunohistochemical methods
to analyze 23 autopsy-confirmed PSP brains.
Results: WBs showed an unexpected abundance of insoluble tau in white and gray matter of PSP brains, but biochemical tau
pathology in white matter was not correlated with immunohistochemistry using the same panel of epitope-specific anti-tau
antibodies used for WB. Despite heterogeneity in the representation of pathological 3R and 4R tau isoforms in cortical versus
subcortical regions, biochemically detectable white matter tau pathology is a constant feature of PSP.
Interpretation: These studies show additional similarities between PSP and corticobasal degeneration, but unlike corticobasal
degeneration, more abundant white matter tau pathology in PSP is detectable by WB than by immunohistochemistry. The
differential detection of abnormal tau by biochemistry versus microscopy in PSP may reflect distinct pathological mechanisms,
and elucidation of these processes will augment efforts to develop better strategies for the diagnosis and treatment of PSP and
related neurodegenerative tauopathies.
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Progressive supranuclear palsy (PSP) is a neurodegen-
erative disorder characterized by postural instability,
rigidity, parkinsonism, supranuclear gaze palsy, and
cognitive abnormalities, including dementia, in asso-
ciation with prominent cortical and subcortical neu-
ronal and glial tau pathology (reviewed in Cairns and
colleagues,1 Dickson,2 Forman and colleagues,3 and
McKhann and colleagues4). Thus, PSP shares pheno-
typic features with frontotemporal dementias and
movement disorders that are classified as tauopa-
thies.1– 4 Tau phosphoproteins bind to microtubules,
and their function is to promote the assembly and
stability of microtubules, thereby playing a pivotal
role in maintaining axonal transport (reviewed in
Buee and colleagues,5 Lee and colleagues,6 and Roy
and colleagues7). In the adult human central nervous
system, six tau isoforms are produced by alternative
splicing. Alternative splicing of exons 2 and 3 results
in the insertion of 0 (0N), 1 (1N), or 2 (2N) 29-
amino acid long motifs near the amino terminus,
whereas splicing of exon 10 results in the inclusion of
either 3 (3R) or 4 (4R) microtubule-binding domains
in the carboxy terminus. From largest to smallest, the
brain tau isoforms are designated 4R2N, 3R2N,
4R1N, 3R1N, 4R0N, and 3R0N, respectively. The
pathological filamentous tau inclusions in PSP are
composed of aberrantly phosphorylated tau proteins,
but there is a preferential accumulation of abnormal
4R tau isoforms in PSP.1– 4 These tau inclusions are
formed by neurons, astrocytes, and oligodendrocytes
in PSP, but similar inclusions also occur in cortico-
basal degeneration (CBD), a 4R tauopathy that shares
genetic and clinical features with PSP, although un-
like PSP, there is abundant white matter tau pathol-
From the 1Department of Pathology and Laboratory Medicine,
Center for Neurodegenerative Disease Research; 2Department of
Neurology, University of Pennsylvania, Philadelphia, PA; 3Michigan
Alzheimer’s Disease Research Center, University of Michigan
Health Center; 4Ann Arbor Affairs Medical Center Geriatric Re-
search Education and Clinical Center, Ann Arbor, MI; 5Depart-
ment of Pathology, University of Utah, Salt Lake City, UT; and
6Memory and Aging Center of the University of California, San
Francisco, CA.
Received Jan 5, 2006, and in revised form Apr 25. Accepted for
publication May 9, 2006.
This article includes supplementary materials available via the Internet
at http://www.interscience.wiley.com/jpages/0364-5134/suppmat
Published online Jul 5, 2006, in Wiley InterScience
(www.interscience.wiley.com). DOI: 10.1002/ana.20916
Address correspondence to Dr Lee, The Center for Neurodegenera-
tive Disease Research, Department of Pathology and Laboratory
Medicine, University of Pennsylvania School of Medicine, HUP/
Maloney 3, 3600 Spruce Street, Philadelphia, PA 19104-4283.
E-mail: vmylee@mail.med.upenn.edu
© 2006 American Neurological Association 335
Published by Wiley-Liss, Inc., through Wiley Subscription Services
ogy in CBD that can be detected by tau immunohis-
tochemistry (IHC).1– 4,8 –11
However, because the presence of pathologically in-
soluble tau detected with biochemical methods in a
neurodegenerative tauopathy may not be evident mi-
croscopically as tau inclusions,12,13 we examined this
possibility in PSP. To do this, we analyzed tau pa-
thology in 23 clinically and neuropathologically con-
firmed PSP cases with respect to the distribution of
tau lesions and the biochemical profile of abnormal
tau isoforms in multiple cortical gray and white mat-
ter regions, as well as subcortical brain regions. Re-
markably, these studies demonstrated an unexpected
abundance of tau pathology in white matter that was
detected biochemically, but not by microscopic exam-
ination using the same panel of epitope-specific tau
antibodies. Although this reflects incompletely under-
stood differences in the pathological modifications
of tau in PSP, we anticipate that clarification of this
conundrum will accelerate efforts to improve the




Brain tissue samples used in this study were obtained from
the Alzheimer’s Disease Centers of the University of Penn-
sylvania School of Medicine, the Columbia University Col-
lege of Physicians and Surgeons, the University of Michigan,
and the University of California San Francisco. The diagnos-
tic clinical and neuropathological assessment of all cases was
performed according to accepted guidelines, and patients
with PSP, Alzheimer’s disease (AD), and CBD met consen-
sus criteria for clinical and neuropathological diagnosis as de-
scribed previously.4,9,14–18 Demographic and other key clin-
ical information on the subjects studied here are summarized
in the Table.










1 9.5 1,185 M 63 10  No 4R3R
2 8.0 1,580 M 46 2  Yes 4R3R
3 12.0 1,185 F 79 2  No 4R3R
4 19.0 1,240 F 68 7  No 4R3R
5 6.5 1,247 F 65 7  No 4R3R
6 10.5 1,380 M 69 4  No 4R3R
7 4.5 1,190 F 62 7  No 4R3R
8 19.0 1,324 F 67 11  No 4R3R
9 19.5 1,308 M 68 6  No 4R3R
10 10.0 1,136 F 80 2  No 4R3R
11 5.0 1,340 M 71 10  No 4R3R
12 5.5 1,160 F 71 8  Yes 4R3R
13 6.0 1,170 F 68 7  No 4R3R
14 10.0 1,450 M 74 7  No 4R3R
15 NA 1,276 F  No 4R3R
16 4.0 1,430 M 75 9  No 4R3R
17 6.0 1,060 M 81 6  No 4R3R
18 16.5 1,064 F 79 11  No 4R3R
19 4.0 1,234 F 66 6  Yes 4R3R
20 2.0 1,350 M 81 15  No 4R3R
21 NA 1,240 M 63 4  Yes 4R3R
22 2.0 NA F 71 6  Yes 4R3R
23 7.0 1,332 F 68 4  No 4R3R
CBD 1 6.5 1,141 F 64 7  No 4R3R
CBD 2 5.0 1,182 F 62 8  No 4R3R
AD 1 4.5 1,019 F 79 8  No 4R3R
AD 2 8.0 1,062 M 80 6  No 4R3R
AD 3 5.0 1,100 M 79 5  No 4R3R
Twenty-three progressive supranuclear palsy (PSP), two corticobasal degeneration (CBD), and three Alzheimer’s disease (AD) patients were used
for this study. In 21 of 23 cases, tau haplotypes were identified as H1/H1 and A0/A0 (data not shown).
aFamily members other than a proband were diagnosed with neurodegenerative disorder.
b4R and 3R  four and three microtubule-binding domains in the tau molecule correspondingly. The ratio 4R/3R was assessed based on
semiquantitative evaluation of Western blot analyses.
PMI  postmortem interval, hours; NA  information is not available;   mild cognitive impairment;   progressive dementia,
  severe dementia.
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Fig 1. Comparative immunohistochemical (IHC) analysis of tau pathology in progressive supranuclear palsy (PSP). Single- and
double-label immunoflourescence staining to show the individual localization (A, B) and coexpression (C, overlay) of
phosphorylation-dependent (Pd) PHF1 and phosphorylation-independent (Pi) N-tau epitopes in frontal cortex and medulla of PSP
brains. Numerous PHF1 (red) and N-tau–positive (green) lesions were detected in the frontal cortex and medulla from two PSP
cases (1 and 2). Although individual immunolabeling with PHF1 or N-tau showed numerous tau inclusions throughout the cortical
gray matter (arrows; A, B), both tau epitopes were colocalized only to a small subset of cells (arrowheads; C, overlay). In compari-
son with N-tau antibodies, PHF1 labeled less tau inclusions. In the cortical white matter, PHF1 and N-tau immunoreactivity was
confined to a subset of single-labeled threadlike structures and to sparsely distributed glial cells. In medulla, colocalization of PHF1
and N-tau epitopes varied from partial overlap in a subset of neurons (Case 1) to numerous double-labeled cells (Case 2).
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Immunohistochemistry
Tissue samples were collected at autopsy and fixed in 10%
neutral-buffered formalin. The brain regions examined here
included frontal, temporal, parietal, and occipital lobes; cer-
ebellum; basal ganglia; and the brainstem after samples were
paraffin embedded and processed for neuropathological as-
sessment. Also, frozen tissue from areas adjacent to blocks of
frozen brain used for biochemical analyses (see later) were
similarly fixed in neutral-buffered formalin, paraffin embed-
ded, and examined as described here and in previous stud-
ies.9,12,14,16–18 To do this, we cut 6m-thick sections and
assessed them with and without antigen retrieval methods
(eg, with formic acid [FA] pretreatment) for the presence of
tau pathology using a panel of previously described epitope-
specific and other tau antibodies9,12,14,16–19 including the
phosphorylation-independent (Pi) rabbit polyclonal anti-
recombinant human tau antibody (17025; dilution
1:10,000) and rabbit polyclonal antibody raised against the
peptide [AEPRQEFEVMEC] at the N terminus of human
tau (N-tau; 1:1,000). In addition, a phosphorylation-
dependent (Pd) tau monoclonal antibody (MAb) PHF1 (1:
500; a gift from Dr P. Davies) also was used for IHC anal-
ysis, whereas an affinity-purified rabbit polyclonal exon 10–
specific (E10; dilution 1:1,000) tau antibody was used to
demonstrate the distribution of 4R tau isoforms in tau le-
sions in PSP. Double-immunofluorescence IHC was con-
ducted to determine the localization of N-tau and PHF1
epitopes in tau lesions by previously described methods19 us-
ing donkey anti–rabbit fluorescein isothiocyanate–conjugated
or donkey anti–mouse TxR-conjugated secondary antibodies
(Jackson ImmunoResearch Laboratories, West Grove, PA)
diluted 1:100 and 1:200 in phosphate-buffered saline, re-
spectively. Finally, Gallyas silver staining was performed to
detect fibrillary lesions, as described previously.9,12,14,16–19
Biochemical and Quantitative Western Blot Analyses
Frozen tissue samples from multiple cortical and subcortical
brain regions of most cases were used for the biochemical
analysis. Gray and white matter regions were dissected and
processed separately as described previously.9,12–14,18,19 Solu-
ble and sarkosyl-insoluble tau proteins were prepared and
dephosphorylated using alkaline phosphatase from Esche-
richia coli (Sigma, St. Louis, MO), as described previ-
ously.9,12–14,18,19 Samples were resolved on 7.5% sodium
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis
(PAGE). Nitrocellulose replicas from each gel were probed
with a mixture of Pi anti-tau MAbs T14 (dilution 1:3,000;
N-terminal, 141–178 residues) and T46 (dilution 1:1,000;
C-terminal, 404 – 441 residues). For phosphoepitope analy-
sis of insoluble tau in nondephosphorylated samples, the
following MAbs were used: phosphorylation-dependent
(Pd) antibodies PHF1 (dilution 1:1,000; Ser396/Ser404)
and AT8 (dilution 1:1,000; Ser202/Thr181 Innogenetics,
Belgium). Bound antibodies were visualized using En-
hanced Chemiluminescence (ECL) kits (Perkin-Elmer, Oak
Brook, IL) according to the manufacturer, and after strip-
ping, the same nitrocellulose replicas were reprobed with
other anti-tau antibodies. For quantitative Western blot
analysis, anti–mouse [I-125]-IgG was used, and quantitative
data were generated using ImageQuant analysis software
(Molecular Dynamics, G.E. Healthcare, USA) as described
previously.9,12–14,18,19 For regional analysis of tau pathol-
ogy, final data were presented as a ratio of a relative
amount of insoluble tau isolated from each brain region
compared with that in the basal ganglia, wherein are abun-
dant amounts of sarkosyl-insoluble tau in PSP brains Anti-
bodies, 17025, N-Tau, E10, T14 and T46 were generated
from our laboratory.
Sequential Extraction of Tau Proteins
Selected brain areas were used for the sequential extraction of
tau proteins with buffers/solutions of increasing stringency,
as described previously.12,13,18,19 The following buffers with
a mixture of protease inhibitors were used: (1) high-salt
buffer (0.75M NaCl, 50mM tris(hydroxymethyl)amin-
omethane [Tris] buffer, 2mM EDTA, pH 7.4; (2) 1% Tri-
ton X-100 in Buffer 1 (Sigma); (3) radioimmunoprecipita-
tion assay buffer (0.1% SDS, 1% NP-40, 0.5% sodium
deoxycholate, 2mM EDTA, 150mM NaCl, 50mM Tris
buffer, pH 8.0); (4) 2% SDS; and (5) 80% FA. Each extrac-
tion step was repeated twice. After each extraction, samples
were spun at 45,000g for 30 minutes at 4°C, after which
supernatants were collected and subjected to Western blot
analysis. Protein concentrations were adjusted between sam-
ples from each extraction.
Apolipoprotein Genotyping and Tau
Haplotype Analyses
DNA was isolated from brain tissue using a commercial kit
(Qiagen, Valencia, CA). Apolipoprotein E genotyping was
performed by using a previously described polymerase chain
reaction restriction fragment length polymorphism meth-
od.14,20 Tau gene (microtubule-associated protein tau
[MAPT]) haplotype analysis was performed by polymerase
chain reaction amplification of exon 9, followed by restric-
tion digestion with HpaII and HpyCH4IV to genotype for
the three known polymorphisms of exon 9 that segregate
with the known major MAPT haplotypes.21,22
Results
Immunohistochemical Distribution of Tau Pathology
in Progressive Supranuclear Palsy Brains
The distribution of tau lesions in cortical and subcor-
tical regions of PSP brains has been well described, and
the IHC observations here concurred with data from
previous studies as illustrated in four representative
PSP cases showing morphologically evident tau lesions
that were more abundant in gray versus white matter
regions (data not shown), but brainstem and basal gan-
glia were most affected. This distribution was confirmed
in Gallyas-stained preparations, and these findings con-
trasted with comparable IHC data from CBD brains
wherein cortical, as well as subcortical, white matter
showed abundant tau pathology by light microscopy
(data not shown). Double-immunofluorescence IHC us-
ing Pi N-tau (green) and Pd PHF1 (red) antibodies
(Fig 1) showed that neuronal and glial tau inclusions in
PSP were immunopositive for both antibodies, al-
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Fig 2. Quantitative Western blot analysis of pathological tau proteins in progressive supranuclear palsy (PSP). Aliquots of sarkosyl-insoluble
fractions from multiple brain regions were dephosphorylated and resolved on 7.5% SDS-PAGE. Mixture of six recombinant human tau
proteins (Rt) were used as standards. To estimate total insoluble tau pool, we probed nitrocellulose replicas with a mixture of monoclonal
antibodies (MAbs) T14 and T46. (A). Brain region-specific distribution of pathological tau in four PSP cases. The amounts of insoluble
tau were variable among cases, but they were consistently higher in cortical white matter of PSP brains. (B). Quantitative assessment of
sarkosyl-insoluble tau in different brain regions. For quantitative Western blot analysis, anti–mouse [I-125]-IgG was used, and quantitative
data were generated using ImageQuant analysis. Each bar represents a relative amount of insoluble tau isolated from 1gm of PSP brain
tissue as a percentage of a total amount of the latter in PSP basal ganglia. (C). The nitrocellulose replica here was subjected to Western
blot analysis using a mixture of MAbs, Tau14 and Tau46 (top panels), after which the same membrane was stripped and reprobed with
rabbit polyclonal E10-specific tau antibody that selectively recognizes all 4R tau isoforms in the PSP samples and in Rt mixture (bottom
panels). (D). Immunohistochemical (IHC) analysis of two representative PSP cases with similar levels of pathological 4R and 3R (4R3R)
isoforms or predominantly 4R tau (4R3R) isoforms. BG  basal ganglia; Ctx  cortex; Fg  frontal cortex, gray matter; Fw  white
matter; M1, 2, 3  medulla levels 1, 2, and 3 dissected for study as per the diagram in Figure 3; Og  occipital cortex, gray matter;
Ow  occipital cortex, white matter; P  pons; Pg  parietal cortex, gray matter; Pw  parietal cortex, white matter; Tg  temporal
cortex, gray matter; Tw  temporal cortex, white matter.
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though PHF1 and N-tau immunoreactivity only colo-
calize about 25 to 50% of the time, and the N-tau
antibody generally detected more tau lesions than
PHF1.
Biochemical Assessment of Pathological Tau in
Progressive Supranuclear Palsy
Western blot analysis of sarkosyl-insoluble tau fractions
from multiple cortical and subcortical regions was per-
formed to evaluate the extent of tau pathology in PSP
brains and to compare these data with the IHC find-
ings from the same brain regions. All samples were de-
phosphorylated using alkaline phosphatase from E. coli,
and representative images of nitrocellulose replicas
probed with a mixture of Pi MAbs T46/T14 are shown
in Figure 2A. In all PSP cases, sarkosyl-insoluble tau
was most abundant in basal ganglia and brainstem
compared with cortical regions; this is consistent with
IHC studies reported here and elsewhere.2,5,8,13 A sim-
ilar biochemical tau profile was also detected by 17025
and N-tau rabbit polyclonal antibodies (data not
shown).
A quantitative Western blot tau profile for PSP was
obtained, and the relative amounts of extracted insolu-
ble tau from each brain region were presented as a per-
centage of the latter in basal ganglia (see Fig 2B). Un-
expectedly, in more than 70% of PSP cases (19/23),
the amount of insoluble tau in the cortical white mat-
ter was variable, but appreciably higher than in the
gray matter from the same brain regions despite a low
abundance of IHC-detectable tau inclusions in sections
adjacent to the regions examined by Western blots
here. Thus, although our IHC data confirm the previ-
ously reported abundance of microscopic tau pathology
in PSP gray matter and the paucity of tau lesions in
PSP white matter, our novel biochemical data demon-
strate a previously unrecognized accumulation of
pathological tau in PSP white matter.
Dephosphorylated samples from different brain re-
gions were used to characterize the representation of
3R and 4R tau isoforms in soluble and sarkosyl-
insoluble fractions from different PSP cases. Analysis of
tau isoforms in multiple brain regions from 23 PSP
cases showed a variable mixture of 3R and 4R tau iso-
forms in the cortical regions in 15 cases, whereas 4R
tau species were overrepresented in 7 cases (see Fig
2A). Rabbit polyclonal E10-specific tau antibody dem-
onstrated 4R tau isoforms in sarkosyl-insoluble prepa-
ration and the extent of pathology in E10-positive tau
lesions (see Fig 2C). Furthermore, although all six tau
isoforms were detected by a mixture of T14 and T46
MAbs (see Fig 2C), E10-specific antibody selectively
recognized only 4R tau isoforms in each sample and in
the standard mixture of human recombinant tau pro-
teins. IHC analysis of two PSP cases with 4R approx-
imately the same as 3R and with 4R greater than 3R
tau isoforms composition is shown in Figure 2D, and
in both of these cases, E10-immunopositive neurofi-
brillary tangles in neurons, as well as glial tau inclu-
sions and threads, were detected in cortical gray and
white matter, as well as in brainstem. In PSP cases with
4R isoform overexpression, the number of E10-positive
structures, particularly in the white matter, was notably
higher.
Predominant expression of 4R tau isoforms was a
distinct signature of pathological tau in brainstem
structures, and in a subset of PSP cases, the 4R2N tau
pathological isoform was more prominent than other
tauopathies (Figs 3A, B). Interestingly, in the brain-
stem from AD brains, insoluble tau profile recapitu-
lated a cortical pattern of tau isoforms with all six iso-
forms being present (see Fig 3A, bottom panel). To
determine whether the ratio of tau isoforms is altered
for normal tau in PSP, we evaluated soluble fractions
from the cortex and the brainstem in PSP cases using a
quantitative Western blot analysis. In contrast with dif-
ferential overrepresentation of 4R tau isoforms in
sarkosyl-insoluble fractions from the cortex and the
brainstem, the 4R:3R tau isoform ratio in correspond-
ing soluble fractions from different PSP cases was ap-
proximately 1 (see Figs 3Aa and 3Ab). Finally, we
compared the biochemical profile of spinal cord tau
pathology in PSP with that in AD, which showed that
the amounts of pathological tau proteins in PSP spinal
cord were higher than in AD spinal cord, and there
was a predominance of 4R tau in PSP spinal cord,
whereas AD spinal cord showed similar amounts of 3R
and 4R tau (see Fig 3C). Similar biochemical studies
were performed on cortical gray and white matter from
prospectively followed cognitively normal individuals,
and these studies confirmed the absence of pathological
tau proteins in these normal brain samples (see Supple-
mentary Figure).
Representative Western blots comparing sarkosyl-
insoluble tau extracted from PSP, CBD, and AD
brains are shown in Figure 4, where distinct profiles of
pathological tau for each disorder are evident. For ex-
ample, in gray matter of AD cortex, the amounts of
pathological tau were substantially higher than in PSP
and CBD cortices, whereas in adjacent AD white mat-
ter, it was more moderate. Furthermore, cortical tau
pathology in PSP was more moderate than AD or
CBD, and the amount of pathological tau in PSP
white matter was substantially higher than in the cor-
responding gray matter, which contrasts sharply with
our IHC data on microscopically evident tau lesions
(see Figs 1A–C). In CBD, the amounts of sarkosyl-
insoluble tau correlated well with abundant tau-
positive inclusions in both anatomical regions (see Figs
1 and 4B). Furthermore, representative Western blots
of tau in fractions sequentially extracted with buffer of
increasing strength (ie, from high-salt buffer to FA)
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from the temporal cortex of PSP, CBD, and AD case
are shown in Figure 5. These data show no significant
difference in the soluble tau fractions among PSP,
CBD, and AD, but there is a distinctive tau solubility
profile in radioimmunoprecipitation assay, SDS, and
FA fractions from each of these three tauopathies.
Thus, the significant differences in quantities of insol-
uble tau detected in PSP, CBD, and AD suggest there
is a differential solubility of pathological tau species in
these tauopathies.
To further characterize the biochemical properties
of pathological tau proteins in cortical gray and white
matter in PSP, we analyzed the distribution of tau
phosphoepitopes in different brain regions in PSP
(Fig 6). Nondephosphorylated sarkosyl-insoluble sam-
ples were used for Western blot analysis. A mixture of
tau-specific Pi MAbs, T14/T46 was used to estimate a
total sarkosyl-insoluble tau pool in the gray and white
matter in two PSP cases. To demonstrate the relative
level of site-specific phosphorylation and to compare
it with the total amounts of insoluble tau, we re-
probed the same nitrocellulose replicas with Pd MAbs.
PHF1 specific for Ser-396/404 and AT8 that recog-
nize Ser202/Thr-205 detected predominantly 64 and
68kD tau species. Also, although the amounts of
T14/T46-positive sarkosyl-insoluble tau in the corti-
Fig 3. The biochemical profile of pathological tau proteins differs in subcortical versus cortical regions of the progressive supranuclear
palsy (PSP) brain. Sarkosyl-insoluble tau was extracted from different regions of the PSP brainstem and spinal cord, as well as from
Alzheimer’s disease (AD) cases. (A, top panel) Western blot analysis of tau proteins in PSP brainstem and cortex. The total amounts of
insoluble tau in the PSP brainstem are higher than in PSP cortex, and 4R tau isoforms (4R2N, 4R1N, 4R0N) predominate. (Middle
panel) Quantitative Western blot analysis of soluble and insoluble tau in PSP. (Bottom panel) Comparative analysis of pathological tau
in the brainstem and frontal cortex of two AD patients (AD 1 and AD 2). Asterisks identify lanes in which the amount of sample
from AD cortex loaded onto the gel was only 20% of that from PSP cortex. (B) Schematic diagram of the brainstem to show the dif-
ferent levels at which samples were taken for study from the pons (P1 and P2) and medulla (M1-3). (C) Biochemical profile of spinal
cord tau pathology in PSP (n  3) and AD (n  2). The amounts of pathological tau proteins in PSP spinal cord were higher than
in AD spinal cord, and there is a predominance of 4R tau in PSP spinal cord, whereas AD spinal cord shows similar amounts of 3R
and 4R tau. Fg  frontal cortex, gray matter; Fw  frontal cortex white matter; M1, 2, 3  medulla levels 1, 2, and 3; P  pons;
Tg  temporal cortex, gray matter; Tw  temporal cortex, white matter.
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cal white matter was substantially higher than in the
adjacent gray matter, PHF1 and AT8 immunoreactiv-
ity was significantly lower in the same samples, sug-
gesting a reduction in the phosphorylation of selected
phosphoepitopes in the white matter in PSP.
Finally, there were no differences in the apolipopro-
tein E genotypes or MAPT haplotypes among the PSP
cases here with respect to the tau pathologies described
earlier.
Discussion
In this study, we combined quantitative Western blot
and IHC analyses of cortical and subcortical brain re-
gions from 23 well-characterized PSP patients to
characterize the profile and distribution pattern of tau
pathologies and their isoform composition with par-
ticular emphasis on the gray versus white matter bur-
den of these tau pathologies. Despite numerous com-
parative studies of PSP neuropathology, quantitative
biochemical assessment of the distribution of tau pa-
thology in gray versus white matter of multiple PSP
brain regions has not been reported to complement
information on microscopic tau lesions demonstrated
by IHC.2,8,10,13,22 However, there is evidence that the
biochemical detection of pathologically insoluble tau
may not be reflected by microscopically evident tau
lesions.12,13 Thus, our study was designed to address
this issue in PSP by pursuing the multicenter collab-
orative investigation described here. Remarkably, al-
though many of the observations in this large cohort
of PSP cases confirmed previous studies of smaller
numbers of PSP brains,2,8,10,13 we present novel data
showing an unexpected abundance of biochemically
detectable tau pathology in both white and gray mat-
ter despite that the insoluble tau in white matter was
not apparent microscopically in sections of contigu-
ous brain samples. Moreover, although we observed
heterogeneity in the representation of pathological 3R
and 4R tau isoforms in cortical versus subcortical re-
gions across these PSP cases, biochemically detectable
white matter tau pathology was a constant feature of
PSP.
Although the burden of microscopic neocortical tau
pathology correlates well with progressive cognitive
decline and dementia in AD, only mild or moderate
amounts of cortical gray matter tau lesions may be
seen microscopically in the brains of PSP patients
with dementia.1,2,4,5,8,11 Although the burden of neu-
rofibrillary tangles and glial tau pathology in PSP pa-
tients in this study with cognitive impairment was
higher than in patients with relatively preserved mem-
ory and cognition, cortical tau lesions were sparse
compared with abundant tau lesions in subcortical
brain regions. The presence of previously undetected
abundant white matter tau pathology demonstrated
here by Western blots, but not by IHC, are signifi-
cant for understanding the pathogenesis and clinical
manifestations of PSP because they imply that the
heretofore unappreciated white matter tau pathology
we demonstrate biochemically in PSP could underlie
cognitive and motor impairments in PSP. These find-
ings also may have diagnostic implications for PSP if,
for example, they can be exploited in neuroimaging
Fig 4. Comparative analysis of sarkosyl-insoluble tau in pro-
gressive supranuclear palsy (PSP), corticobasal degeneration
(CBD), and Alzheimer’s disease (AD). (A) Representative
Western blots of sarkosyl-insoluble tau proteins in AD, CBD,
and PSP. To avoid the saturation of enzyme chemilumines-
cence (ECL) signal due to substantial differences in the
amounts of pathological tau among cases, we loaded only 20%
of the material extracted from selected AD samples compared
with the PSP and CBD cases (asterisks). (B) Quantitative
Western blot analysis was used to compare relative amounts of
insoluble tau proteins in different neuropathological conditions.
Fg  frontal cortex, gray matter; Fw  frontal cortex white
matter; Og  occipital cortex, gray matter; Ow  occipital
cortex, white matter; Pg  parietal cortex, gray matter;
Pw  parietal cortex, white matter; Tg  temporal cortex,
gray matter; Tw  temporal cortex, white matter.
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studies to detect white matter abnormalities that fa-
cilitate distinction of PSP from other clinically similar
neurodegenerative disorders. However, further studies
are needed to test these hypotheses.
Biochemically, the amounts of sarkosyl-insoluble tau
in the white matter were higher than in adjacent gray
matter in the majority of PSP cases, and this also has
been described in CBD9 and Pick’s disease.12 How-
ever, although the biochemical findings in CBD corre-
late well with the abundance of tau-immunopositive
lesions detected by IHC in gray and white matter of
CBD,9 and similar correlations apply to PSP gray
matter, enigmatically, this is not the case for white
matter tau pathology in PSP.
Initially, the biochemical profile of pathological tau
isoforms in PSP cortex was thought to be composed
almost exclusively of 4R tau isoforms similar to CBD,
but our data here, and other recent reports, indicate
that there may be a variable mixture of pathological
3R- and 4R- tau isoforms in some PSP and CBD
brains.2,8,9 Based on our results, all PSP cases exam-
ined here could be divided into two major groups as
a function of their cortical profile of pathological tau
isoforms: (1) those with variable mixture of 3R and
4R tau isoforms, and (2) those with predominantly
4R tau isoforms. In contrast, 4R tau isoforms were
significantly overrepresented in subcortical regions
and brainstem regardless of the tau isoform profile in
cortex of the same PSP brains.
Although there is a well-documented association be-
tween sporadic PSP and single nucleotide polymor-
phisms in the MAPT gene, similar associations have
been reported for sporadic CBD, and it is unclear how
these single nucleotide polymorphisms influence the
onset or progression of PSP or the biochemical profile
of pathological tau in PSP.2,21,22 Consistent with these
earlier observations, 21 of our 23 cases were found to
have an H1/H1 and A0/A0 MAPT single nucleotide
polymorphisms profile.
In conclusion, PSP is characterized by a distinct bio-
chemical profile of pathological tau proteins, and al-
Š Fig 5. Tau solubility profile in progressive supranuclear palsy
(PSP), corticobasal degeneration (CBD), and Alzheimer’s dis-
ease (AD). Here, 0.3gm of frozen temporal cortex from PSP
and AD brains were used for sequential extraction of tau with
buffers/solutions of increasing stringency in the following se-
quence: lane 1  Buffer A (0.75M NaCl, 50mM tris(hy-
droxymethyl)aminomethane buffer, pH 7.4, 2mM EDTA);
lane 2  1% Triton in Buffer A; lane 3  radioimmuno-
precipitation assay buffer; lane 4  2% sodium dodecyl sul-
fate (SDS); lane 5  70% formic acid (FA). Each extraction
step was repeated 2 times with same buffer/solution, and after
each extraction, samples were spun at 45,000g for 30 minutes
at 4°C so that aliquots from the resulting supernatants could
be subjected to Western blot analysis using a mixture of mono-
clonal antibodies (MAbs) Tau14 and Tau46. Due to the sig-
nificant differences in tau immunoreactivity between the ex-
tracts, the amount of sample used for analysis was adjusted as
a percentage of the total extractable tau (soluble  insoluble)
to avoid saturating the Western blot signal for some lanes so
that lane 1 is 1% of total, lanes 2 to 4 are 2% of total, and
lane 5 is 35% of total. Equal amounts from each extract were
loaded for PSP, CBD, and AD. Samples from the first extrac-
tion step are for PSP, CBD, and AD. (Top) The tau solubil-
ity profile in PSP shows gray and white matter separately.
Note that the amount of 2% SDS soluble tau proteins is
higher in the white matter than in the corresponding gray
matter. No detectable immunoreactivity was found in the FA
extract. (Middle) Sequential extraction from a CBD case also
is shown. (Bottom) Soluble and insoluble tau pool in AD is
shown. Although the amounts of 2% SDS and FA-soluble tau
are substantially higher in the gray matter compared with PSP
and CBD, only a fraction of this signal is detected in the un-
derlying white matter in AD.
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though this is similar to CBD, white matter tau pa-
thology is far more abundant in CBD compared with
PSP. Although white matter tau pathology is seen in
other tauopathies in addition to PSP and CBD, it re-
mains unclear what role glial and white matter tau pa-
thology plays in mechanisms of brain degeneration in
these tauopathies. However, it is likely that further in-
sight into these issues could lead to better strategies for
the diagnosis and treatment of PSP and related neuro-
degenerative tauopathies.
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